Leniolisib for Immune Dysregulation in PIDs

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Primary Immunodeficiency Disorders (PIDs)

Interventions

DRUG

Leniolisib

The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).

Trial Locations (1)

RECRUITING

National Institute of Health, Bethesda